{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:pubmed-pmid-42158165-semaglutide:v1","objectPathId":"pubmed-pmid-42158165-semaglutide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/pubmed-pmid-42158165-semaglutide/","json":"https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-42158165-semaglutide-v1.json","markdown":"https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-42158165-semaglutide-v1.md"},"story":{"slug":"pubmed-pmid-42158165-semaglutide","version":1,"domain":"Literature metadata","dateInSource":"2026-08-13","sourceCheckedAt":"2026-08-14","publishedAt":"2026-08-14","peptideSlugs":["semaglutide"],"peptides":[{"slug":"semaglutide","url":"https://peptidescanner.com/peptides/semaglutide/"}]},"claims":[{"id":"headline","text":"Semaglutide use for hypothalamic obesity and type 2 diabetes mellitus after suprasellar germinoma treatment.","sourceIds":["pubmed-observation-pmid-42158165-2026-08-13-ccb89642cb0b"]},{"id":"summary","text":"PubMed lists PMID 42158165 in JCEM case reports as Case Reports, Journal Article, with publication-date metadata of 2026-05-18 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-42158165-2026-08-13-ccb89642cb0b"]},{"id":"paragraph-1","text":"PubMed lists PMID 42158165 in JCEM case reports as Case Reports, Journal Article, with publication-date metadata of 2026-05-18 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-42158165-2026-08-13-ccb89642cb0b"]},{"id":"paragraph-2","text":"This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth.","sourceIds":["pubmed-observation-pmid-42158165-2026-08-13-ccb89642cb0b"]}],"sources":[{"id":"pubmed-observation-pmid-42158165-2026-08-13-ccb89642cb0b","name":"PubMed","sourceClass":"A","title":"Semaglutide use for hypothalamic obesity and type 2 diabetes mellitus after suprasellar germinoma treatment. · retained source version 1:2026-08-13:current:ccb89642cb0b45e2091f4c302f091c0ec37fe096014974289b8bc6418e48c159","url":"https://pubmed.ncbi.nlm.nih.gov/42158165/"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"240bb10725d6030c9d474131bc1490531d6b7227bc9aecad639e70e26666c70b","tierARecordSha256":"8f2eff43f33861ad6a8dc5e45d70bf68ba5bc43adad796657047f63ea1679184"},"integrity":{"algorithm":"sha256","contentSha256":"305c63767f7cecd5b71e5f946e194caee9192b9c056bdfdc032fe5e50c0586f5"}}